CAR T-Cell Therapy Market, Unlocking New Horizons for Cancer Treatment, Poised to Reach US$ 23.4 Bn by 2031

The global CAR T-cell therapy market is poised for substantial growth in the coming years. Projected to expand at a Compound Annual Growth Rate (CAGR) of 22.5% from 2024 to 2031, the market is anticipated to increase from a value of US$ 5.6 billion in 2024 to US$ 23.4 billion by 2031. This surge in market growth is primarily driven by the increasing incidence of cancer worldwide, significant investments in research and development, government funding, and the expanding adoption of chimeric antigen receptor (CAR) T-cell therapies as a viable treatment option.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/28264

CAR T-cell therapy, a promising form of immunotherapy, involves the genetic modification of a patient's own T-cells to fight cancer more effectively. The market is witnessing rapid expansion due to an escalating number of cancer cases, with projections suggesting that over 2 million new cancer diagnoses will be made in the U.S. in 2024 alone. Furthermore, the market is heavily influenced by continuous innovations in CAR T-cell therapy products, such as Yescarta (axicabtagene ciloleucel), which holds a significant market share due to its efficacy in treating cancers like large B-cell lymphoma. North America leads the global CAR T-cell therapy market, accounting for a dominant share in 2024, while the Asia-Pacific region is set to become the fastest-growing market segment, driven by a growing patient population and government support for CAR T-cell therapies.

Key Highlights from the Report

✦ North America is projected to hold a significant 66.9% share of the CAR T-cell therapy market in 2024.
✦ The U.S. is expected to account for over 98.8% of the value share within the North American market in 2024.
✦ Asia-Pacific is expected to become the fastest-growing region in the market by 2031.
✦ Yescarta (axicabtagene ciloleucel) is forecasted to capture over 57.8% of the market share in 2024.
✦ Relapsed large B-cell lymphoma is projected to account for around 90.7% of the market share in CAR T-cell therapy in 2024.
✦ Strong government support and increasing investments in clinical trials are key drivers of market growth.

Market Segmentation

The CAR T-cell therapy market is segmented based on product type, indication, and end-user. The market's leading product is Yescarta (axicabtagene ciloleucel), which is designed for patients with large B-cell lymphoma who have not responded well to conventional therapies. This product is anticipated to hold a dominant share of the market due to its effectiveness in treating aggressive forms of non-Hodgkin lymphoma.

In terms of indications, the treatment of relapsed large B-cell lymphoma holds the largest market share, with nearly 90.7% of the market share attributed to this indication. This reflects the high unmet need for effective therapies for relapsed or refractory large B-cell lymphoma, a cancer that can be difficult to treat with conventional therapies.

Geographically, North America, particularly the U.S., is expected to remain the dominant region in the CAR T-cell therapy market, driven by the presence of leading biotechnology companies and favorable reimbursement policies. Meanwhile, the Asia-Pacific region is expected to experience the highest growth rate, supported by government funding, increasing patient populations, and regulatory approvals for CAR T-cell therapies, such as the approval of Carteyva in China for the treatment of mantle cell lymphoma.

Regional Insights

The CAR T-cell therapy market is geographically diverse, with North America holding a substantial portion of the market share. The U.S. leads the North American market, with its healthcare infrastructure, strong research ecosystem, and government funding providing a conducive environment for CAR T-cell therapy adoption. The presence of major pharmaceutical players, such as Bristol Myers Squibb and Novartis, has significantly contributed to the expansion of the CAR T-cell therapy market in the region.

Asia-Pacific is set to become the fastest-growing market for CAR T-cell therapy. The region's significant growth is driven by a growing cancer patient population and substantial government support for innovative therapies. China, in particular, is witnessing increased investments in clinical trials and regulatory approvals for CAR T-cell therapies. Furthermore, increasing clinical trials in countries such as India and Japan are expected to fuel the regional market's expansion.

Europe is also a key player in the CAR T-cell therapy market, with countries like Germany and the UK investing in cancer research and CAR T-cell production. However, the region's growth is somewhat hindered by stringent regulatory processes and a slower rate of therapy adoption compared to North America.

Market Drivers

The increasing prevalence of cancer is the primary driver of growth in the CAR T-cell therapy market. The rise in cancer rates, particularly aggressive cancers such as lymphoma and leukemia, has led to a growing demand for innovative treatment options like CAR T-cells. The ability of CAR T-cells to target specific cancer cells while sparing healthy tissues has positioned them as an effective alternative to traditional therapies, which often come with severe side effects.

In addition, government support and awareness programs have played a significant role in the adoption of CAR T-cell therapy. Organizations like the American Cancer Society and CancerCare provide resources and financial assistance to cancer patients, promoting awareness of the benefits of CAR T-cell therapy. These efforts, coupled with patient assistance programs (PAPs), are expanding access to CAR T-cell therapies for a broader patient population.

Another key driver is the surge in clinical trials aimed at exploring new applications of CAR T-cell therapies and enhancing their efficacy. As more clinical trials are conducted, new data and insights are generated, driving further advancements in CAR T-cell therapy and expanding its potential to treat various types of cancer.

Market Restraints

Despite its promising potential, the CAR T-cell therapy market faces several challenges that may hinder its growth. One of the most significant barriers is the high cost of CAR T-cell treatments. The personalized nature of the therapy, which involves extracting and modifying the patient's T-cells, leads to substantial production costs. Some therapies can cost upwards of $350,000 per treatment, which limits accessibility, particularly in low- and middle-income countries.

The stringent eligibility criteria for CAR T-cell therapy also pose challenges. Not all cancer patients are eligible for CAR T-cell treatments, as they must have already undergone multiple rounds of chemotherapy or other therapies. Additionally, some patients may be unable to tolerate the side effects of CAR T-cell therapies, such as cytokine release syndrome (CRS), which can complicate treatment decisions.

Furthermore, the lack of standardized manufacturing processes for CAR T-cells in many regions limits the widespread adoption of the therapy. The need for specialized facilities and equipment for CAR T-cell production presents challenges for scaling up treatment availability globally.

Market Opportunities

The CAR T-cell therapy market presents several opportunities for growth. With the increasing number of cancer cases worldwide, there is a growing demand for more personalized and effective treatment options. This demand is expected to drive investments in CAR T-cell research and manufacturing, particularly for novel indications and combination therapies.

The expansion of clinical trials is another significant opportunity. As pharmaceutical companies and research institutions invest in clinical studies for CAR T-cell therapies, the number of approved indications is expected to increase, further expanding the market. Moreover, the development of off-the-shelf CAR T-cell therapies, which do not require customization for each patient, is anticipated to drive down costs and improve accessibility.

In addition, the integration of CAR T-cell therapy with other treatment modalities, such as immune checkpoint inhibitors, holds significant potential. Combination therapies are being explored to enhance the efficacy of CAR T-cells and provide more effective treatment options for patients.

Reasons to Buy the Report

✔ Detailed analysis of the CAR T-cell therapy market, including key growth drivers, trends, and challenges.
✔ Comprehensive segmentation insights, including market share, growth rates, and regional analysis.
✔ In-depth understanding of key players and their market strategies.
✔ Expert forecasts for the CAR T-cell therapy market from 2024 to 2031.
✔ Strategic recommendations for stakeholders to capitalize on emerging market opportunities.

Company Insights

• Gilead Sciences, Inc. - A leader in CAR T-cell therapy with its product Yescarta, approved for the treatment of large B-cell lymphoma.
• Bristol Myers Squibb - Known for its Breyanzi product, a CD19-directed CAR T-cell therapy.
• Novartis - A pioneer in CAR T-cell therapies with its Kymriah product, approved for the treatment of leukemia.
• Johnson & Johnson - Continues to invest in CAR T-cell therapy through its subsidiary Janssen Biotech.
• Celgene Corporation - Focuses on novel therapies, including CAR T-cell products.
• AbbVie - Invests heavily in cancer therapies, including CAR T-cell treatments.

Recent Developments

Boomi (October 2024) - Launched a connector to integrate third-party systems with the Veeva Vault platform, improving collaboration for life sciences data sharing.

JW Therapeutics (2024) - Received approval for Carteyva in China for the treatment of mantle cell lymphoma, expanding its CAR T-cell product portfolio.

Conclusion

The CAR T-cell therapy market is experiencing rapid growth, driven by the increasing prevalence of cancer, supportive government initiatives, and significant investments in research and development. With promising products like Yescarta leading the market, and the growing demand for innovative cancer treatments, the CAR T-cell therapy market is expected to reach new heights

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.